Biomedica on the move 2019
October 10, 2019
Valorising Regenerative Medicine
Brightlands Chemelot Campus
Meet the Euregional regenerative medicine community on October 10. In the regenerative medicine trend a vast majority of the Euregional SMEs and knowledge institutes can benefit. Novel mechanisms of action are developed and pushed forward in the value chain, laboratory & handling infrastructure changes and the need to monitor and measure increases. Progress in Regenerative Medicine provides opportunities for biotechnology ánd medical technology SMEs.
We thank our partners and sponsors for the Biomedica on the Move 2021:
The Interface Entreprises of the University of Liege is focused on open innovation and technology transfer at local and international levels, in several, often cross-disciplinary, fields (life sciences, engineering, social sciences, sustainable developments).
The Euregional Networking Organisations:
The collaborating projects and partners:
The pitching SMEs:
CERHUM (Human Ceramics) Is specialized in 3D printing of ceramic-based medical devices. Our business includes two main activities:
Production of custom bone implants: We have developed a custom bone graft solution called MyBone. In order to ensure a better biocompatibility and bone regeneration with this product, we use the same material that constitutes bone mineral part “hydroxyapatite”.
CDMO for the 3D printing of ceramics: our know-how and our experience in ceramic 3D printing enable us to assist our customers in the development and production of ceramics medical device.
By Islam Bouakaz, Ph.D., Researcher and Project leader at CERHUM
ECLS is an established treatment option for patients with severe circulatory and/or respiratory deficiencies.
We at Hemovent developed a novel ECLS device without legacy.
The MOBYBOX ECLS System is designed from a use perspective and successfully introduced to the market.
By Dr. Oliver Marseille, CTO Hemovent GmbH
Nano-fiber technology has the potential to revolutionize the medical device industry. Nano-fibers mimic the natural environment of cells in the human body in architecture and size-scale. Therefore, implants based on nano-fibers are very well received by the body and unwanted side-effects of implantation, such as inflammation or rejection, are minimized. Instead, the nano-fibers dissolve in time and get replaced by natural tissue. This way, the implant helps the human body to heal itself.
By Sander de Vos, CBO at IME Medical Electrospinning
Lake3D is a young company that focuses on advanced material jetting technologies to print dental prostheses and other medical implants. The company has a cutting edge 3D printer facility which uses printheads traditionally used for the graphical industry. It currently develops new material formulations and software to blend materials and add colours and gloss while printing. Such technology does not exist in the dental industry yet and will create new opportunities for high quality prostheses produced at low cost.
By Petra Doelman MBA, COO Lake3D
medical magnesium develops metallic bioabsorbable implants for orthopaedic and trauma care. The mm.X implants are combining strength of a metal with bioabsorption. Therefore, a second surgery for implant removal is not necessary. First mm.X implants have CE clearance and broadly applied. Our goal is to provide users and patients with customized and highly functional mm.X solutions.
By Kilian Reuß , Co-Founder and CEO medical magnesium
LightFab is a small start-up company started in 2013 by 3 experienced laser scientists from RWTH Aachen University. LF’s mission is to bring the SLE (selective laser etching) technology and other in-volume structuring processes to broad industrial application: LF produces complex 3D precision glass parts for customers in optics, electronics, automotive, medicine, chemistry and other markets, sells the machine to produce 3D glass parts called LightFab 3D Printer and offers services like training, feasibility studies and integration into mass-production environment helping customers to exploit the new technology.
By Martin Hermans , Managing Partner at Lightfab GmbH
In 2020 we started with the delivery of 2-layered treated cotton masks. Then we focused on the development of an (today patented) anti-virus mask with virus-destroying special treated material inside. It was tested and released as medical mask by Hohenstein Institute. Until today we deliver illuminated masks. Also available with anti-virus-layer.
Innovation for the future: medical mask with Corona-detector and LED indicators, if a person is infected or not (green=no, red=infected).
By Dipl. Ing. MBA Björn Sobischek , founder and CEO from FLT – Future Technologies GmbH
UPyTher is a spin-off company (2020) of the Eindhoven University of Technology that specializes in hydrogel drug formulations for application in the peritoneal cavity – intraperitoneal therapy – for the treatment of peritoneal cancer (PC). PC is an underrated type of cancer but forms a major component of treatment failure and cancer-related mortality in patients with prevalent cancers of the colon, stomach and ovaries. Intraperitoneally administered chemotherapy is known to provide local advantages over traditional systemic chemotherapy, but current methods show unsatisfactory outcomes and are not readily available to most patients. With its hydrogel-based specialty formulations UPyTher turns intraperitoneal chemotherapy into a practical and safe treatment alternative that offers improved survival and quality of life for hundreds of thousands of patients with PC.
By Geert C. van Almen, PhD , Managing Director of UPyTher
VACIS is a tissue engineering company focused on soft tissues. For now the first application is growing vascular grafts, for instance for hemodialyses access or bypass. The vascular graft is grown in the body at the location where it is needed. And is therefore patient-own avoiding the challenges of transplants or artificial grafts. The technology is patented. VACIS is in the clinical stage and on track for CE Mark / FDA approval. VACIS is looking for financial and commercial partners.
By Drs. ir Johan van den Arend Schmidt, Director at Vacis